OS Therapies announced positive data for 'OST-HER2' in osteosarcoma clinical trials

TechubNews · 2026-03-09T12:47:25+00:00

OS Therapies Incorporated focuses on the research and development of osteosarcoma and other solid tumors, launching the HER2-targeted vaccine 'OST-HER2' and achieving positive results in clinical trials. The company will continue to update interactions with regulatory agencies such as the FDA and financing information to keep investors informed of development progress.

TechubNews

2026-03-09 12:47:25

Abstract generation in progress

OS Therapies Incorporated continues to release press releases to provide shareholders and investors with the latest information. The company is a clinical-stage oncology and biotechnology firm focused on osteosarcoma and other solid tumors.

Its main R&D pipeline, ‘OST-HER2,’ is a vaccine targeting the HER2 protein. The company previously announced positive Phase 2b data from clinical trials in recurrent metastatic osteosarcoma patients and reported a statistically significant benefit in 12-month event-free survival. Notably, through immune biomarker analysis, the role of interferon gamma pathway biomarkers as potential surrogate indicators of clinical efficacy was highlighted.

Investors can follow @OSTX to stay updated on key interactions with regulatory agencies such as the FDA and EMA, as well as new drug application developments. Additionally, the company’s financing and corporate transaction news are important areas to watch.

Furthermore, updates on OSTX’s veterinary oncology drug development and expansion of its ADC platform will be continuously provided to effectively track the company’s progress. This news source will comprehensively cover OSTX’s significant advances in clinical trials, biomarker discovery, and financial strategy, offering valuable guidance for investors.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.